MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, GUTS had $14,076K increase in cash & cash equivalents over the period. -$90,885K in free cash flow.

Cash Flow Overview

Change in Cash
$14,076K
Free Cash flow
-$90,885K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Issuance of common stock in sept...
    • Change in fair value of warrant ...
    • Issuance of common stock and war...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Accounts payable
    • Operating lease liabilities
    • Others

Cash Flow
2025-12-31
Net loss
-140,954
Depreciation
1,129
Non-cash interest expense
296
Non-cash operating lease expense
1,587
Stock-based compensation expense
6,684
Change in fair value of warrant liabilities
40,901
Change in fair value of notes payable, non-cash
424
Inventory
-73
Prepaid expenses and other current assets
-2,248
Accounts payable
-1,666
Accrued expenses and other current liabilities
414
Operating lease liabilities
-1,278
Other long-term assets and liabilities
186
Net cash used in operating activities
-90,328
Purchases of property and equipment
557
Net cash used in investing activities
-557
Issuance of common stock in connection with at-the-market offering, net of underwriting commissions and offering costs
6,778
Issuance of common stock and warrants in august 2025 public offering, net of underwriting commissions and offering costs
22,587
Issuance of common stock in september 2025 public offering, net of underwriting commissions and offering costs
56,016
Proceeds from issuance of common stock under share purchase agreement
20
Exercises of common stock warrants
19,737
Exercises of common stock options
280
Principal payments on finance lease obligations
457
Net cash provided by financing activities
104,961
Net increase in cash, cash equivalents and restricted cash
14,076
Cash, cash equivalents and restricted cash at beginning of period
71,719
Cash, cash equivalents and restricted cash at end of period
85,795
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Issuance of common stockin september 2025...$56,016K Issuance of common stockand warrants in...$22,587K Exercises of common stockwarrants$19,737K Issuance of common stockin connection with...$6,778K Exercises of common stockoptions$280K Proceeds from issuance ofcommon stock under...$20K Net cash provided byfinancing activities$104,961K Canceled cashflow$457K Net increase incash, cash...$14,076K Canceled cashflow$90,885K Principal payments onfinance lease...$457K Change in fair value ofwarrant liabilities$40,901K Stock-based compensationexpense$6,684K Prepaid expenses andother current assets-$2,248K Non-cash operating leaseexpense$1,587K Depreciation$1,129K Change in fair value ofnotes payable,...$424K Accrued expenses andother current...$414K Non-cash interestexpense$296K Inventory-$73K Net cash used inoperating activities-$90,328K Net cash used ininvesting activities-$557K Canceled cashflow$53,756K Net loss-$140,954K Purchases of property andequipment$557K Accounts payable-$1,666K Operating leaseliabilities-$1,278K Other long-termassets and liabilities$186K

FRACTYL HEALTH, INC. (GUTS)

FRACTYL HEALTH, INC. (GUTS)